Jon Napitupulu

Harrow reaffirmed its 2025 revenue guidance of $270–280 million and outlined an aggressive commercial ramp across its ophthalmology portfolio....

Breakthru Medicine has emerged from stealth with a $60 million Series A following a prior undisclosed seed round, aiming...

Mesoblast posted a decisive second fiscal quarter: Ryoncil gross sales reached $35 million with net revenue of $30 million,...

Scilex Holding Company has made a $20 million strategic investment in Quantum Scan Holdings, a medical technology firm developing...

Avicanna has published prospective real-world evidence from a physician-supervised medical cannabis program in the Canadian Journal of Pain, reporting...

Regeneron posted a muted top line for 2025—fourth quarter revenue up 3% to $3.9 billion and full-year up 1%...

Achieve Life Sciences has granted stock options covering 115,000 shares to five new employees under its 2024 equity inducement...

Nurix Therapeutics has dosed the first patients in DAYBREAK, its registrational program for bexobrutideg (NX-5948) in relapsed/refractory chronic lymphocytic...

Belite Bio will showcase previously disclosed topline results from its Phase 3 DRAGON trial of tinlarebant in adolescents with...

CorMedix will host an in‑person and virtual analyst day on February 10 to showcase its post‑acquisition growth plan, centering...